New Personal Model for Forecasting the Outcome of Patients with Histological Grade III-IV Colorectal Cancer Based on Regional Lymph Nodes
Table 1
Demographics and clinical characteristics of patients in the training and validation group.
Variates
All patients (n = 14039)
Group
value
Training dataset (n = 9828)
Validation dataset (n = 4211)
Age, no. (%)
<45 years old
1423 (10.1)
975 (9.9)
448 (10.6)
0.192
45–60 years old
4777 (34.0)
3384 (34.4)
1393 (33.1)
>60 years old
7839 (55.8)
5469 (55.6)
2370 (56.3)
Sex, no. (%)
Male
7167 (51.1)
5004 (50.9)
2163 (51.4)
0.638
Female
6872 (48.9)
4824 (49.1)
2048 (48.6)
Race, no. (%)
White
11219 (79.9)
7854 (79.9)
3365 (79.9)
0.941
Black
1566 (11.2)
1092 (11.1)
474 (11.3)
Other
1254 (8.9)
882 (9.0)
372 (8.8)
AJCC stage, no. (%)
Stage I
1335 (9.5)
952 (9.7)
383 (9.1)
0.659
Stage II
3148 (22.4)
2187 (22.3)
961 (22.8)
Stage III
6278 (44.7)
4388 (44.6)
1890 (44.9)
Stage IV
3278 (23.3)
2301 (23.4)
977 (23.2)
AJCC T stage, no. (%)
T1
790 (5.6)
557 (5.7)
233 (5.5)
0.569
T2
1204 (8.6)
838 (8.5)
366 (8.7)
T3
7775 (55.4)
5476 (55.7)
2299 (54.6)
T4
4270 (30.4)
2957 (30.1)
1313 (31.2)
AJCC N stage, no. (%)
N0
4767 (34.0)
3335 (33.9)
1432 (34.0)
0.646
N1
4339 (30.9)
3059 (31.1)
1280 (30.4)
N2
4933 (35.1)
3434 (34.9)
1499 (35.6)
AJCC M stage, no. (%)
M0
10761 (76.7)
7527 (76.6)
3234 (76.8)
0.803
M1
3278 (23.3)
2301 (23.4)
977 (23.2)
Grade, no. (%)
Grade III
11721 (84.5)
8198 (83.4)
3523 (83.7)
0.736
Grade IV
2318 (16.5)
1630 (16.6)
688 (16.3)
Histological type, no. (%)
Adenocarcinoma
12112 (86.3)
8480 (86.3)
3632 (86.3)
0.773
AM/MPA
1282 (9.1)
890 (9.1)
392 (9.3)
SRCC
645 (4.6)
458 (4.7)
187 (4.4)
Primary site, no. (%)
Left colon
3495 (24.9)
2445 (24.9)
1050 (24.9)
0.551
Right colon
7645 (54.5)
5376 (54.7)
2269 (53.9)
Rectum
2899 (20.6)
2007 (20.4)
892 (21.2)
LNR, no. (%)
LNR ≤ 0.24
9507 (67.7)
6671 (67.9)
2866 (67.9)
0.551
LNR > 0.24
4532 (32.3)
3157 (32.1)
1375 (32.7)
LODDS, no. (%)
LODDS1
4761 (33.9)
3318 (33.8)
1443 (34.3)
0.509
LODDS2
4690 (33.4)
3313 (33.7)
1377 (32.7)
LODDS3
4588 (32.7)
3197 (32.5)
1391 (33.0)
Examined lymph nodes, no. (%)
Low
1476 (10.5)
1016 (10.3)
460 (10.9)
0.314
High
12563 (89.5)
8812 (89.7)
3751 (89.1)
Negative lymph nodes, no. (%)
Low
3229 (23.0)
2231 (22.7)
998 (23.7)
0.205
High
10810 (77.0)
7597 (77.3)
3213 (76.3)
Metastasis at bone, no. (%)
Yes
101 (0.7)
70 (0.7)
31 (0.7)
0.964
No
13938 (99.3)
9758 (99.3)
4180 (99.3)
Metastasis at brain, no. (%)
Yes
35 (0.2)
28 (0.3)
7 (0.2)
0.268
No
14004 (99.8)
9800 (99.7)
4204 (99.8)
Metastasis at liver, no. (%)
Yes
2086 (14.9)
1456 (14.8)
630 (15.0)
0.844
No
11953 (85.1)
8372 (85.2)
3581 (85.0)
Metastasis at lung, no. (%)
Yes
426 (3.0)
302 (3.1)
124 (2.9)
0.725
No
13913 (97.0)
9526 (96.9)
4087 (97.1)
Survival status, no. (%)
Dead
5418 (38.6)
3813 (38.8)
1605 (38.1)
0.458
Alive
8621 (61.45)
6015 (61.2)
2606 (61.9)
Survival time (month)
33.28 (22.82)
33.49 (22.95)
32.80 (22.51)
0.103
Mean (SD)
AJCC, American Joint Committee on Cancer; T, tumor; N, nodes; M, metastasis; LNR, lymph node ratio; LODDS, the log odds of positive lymph nodes; AM/MPA, mucinous adenocarcinoma\mucin-producing adenocarcinoma; SRCC, signet ring cell carcinoma; SD, standard deviation.
